As a consequence of chronic liver disease progression, severe cirrhosis, decompensation and fibrosis culminates in end-stage liver disease (ESLD). There are no treatment options approved for ESLD, but, among others, regenerative therapies with autologous, nonengineered, pro-regenerative macrophages have shown good tolerability and improved transplant-free survival in the clinical setting.
Resolution Therapeutics Ltd. is preparing for a phase I/II trial of its autologous engineered macrophage cell therapy, RTX-001, in the treatment of end-stage liver disease and has raised £63.5 million (US$83.3 million) to complete the study and to add further fibrotic and inflammatory disease programs to its portfolio. Recruitment to the study, to be conducted at 15 sites in Spain and the U.K., is due to start before the end of 2024, with the monocyte-derived patient macrophages being processed and modified at a facility in Edinburgh.
Resolution Therapeutics Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of its lead candidate RTX-001 in patients with decompensated liver cirrhosis.
Syncona Ltd. has added £10 million (US$13.1 million) to the £26.6 million it put into the series A round of Resolution Therapeutics Ltd., enabling the company to advance an allogeneic version of the macrophage cell therapy it is developing for the treatment of compensated liver disease. Since the first close of the round in December 2020, the company has been working on process development for the autologous product, and patients have continued to be recruited to a 50-patient phase II study being run by the academic founders of Resolution.
LONDON – Syncona Ltd. has unveiled its fifth cell therapy startup, Resolution Therapeutics Ltd., which arrives on the scene with a £26.6 million (US$35.6 million) series A to exploit the ability of macrophages to stimulate liver repair.
